Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/22561
Title: Bifunctional Aptamer-Doxorubicin Conjugate Crosses the Blood-Brain Barrier and Selectively Delivers Its Payload to Epithelial Cell Adhesion Molecule-Positive Tumor Cells.
Authors: Macdonald, Joanna;Henri, Justin;Jamieson, Adelaide;Denoyer, Delphine;Burvenich, Ingrid J G;Pouliot, Normand;Shigdar, Sarah
Affiliation: Centre for Molecular and Medical Research, Deakin University, Geelong, Australia
Department of Pathology, The University of Melbourne, Parkville, Australia
School of Medicine, Deakin University, Geelong, Australia
Matrix Microenvironment and Metastasis Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
School of Cancer Medicine, La Trobe University, Melbourne, Australia
Issue Date: 6-Feb-2020
EDate: 2020
Citation: Nucleic acid therapeutics 2020; online first: 6 February
Abstract: The prognosis for breast cancer patients diagnosed with brain metastases is poor, with survival time measured merely in months. This can largely be attributed to the limited treatment options capable of reaching the tumor as a result of the highly restrictive blood-brain barrier (BBB). While methods of overcoming this barrier have been developed and employed with current treatment options, the majority are highly invasive and nonspecific, leading to severe neurotoxic side effects. A novel approach to address these issues is the development of therapeutics targeting receptor-mediated transport mechanisms on the BBB endothelial cell membranes. Using this approach, we intercalated doxorubicin (DOX) into a bifunctional aptamer targeting the transferrin receptor on the BBB and epithelial cell adhesion molecule (EpCAM) on metastatic cancer cells. The ability of the DOX-loaded aptamer to transcytose the BBB and selectively deliver the payload to EpCAM-positive tumors was evaluated in an in vitro model and confirmed for the first time in vivo using the MDA-MB-231 breast cancer metastasis model (MDA-MB-231Br). We show that colocalized aptamer and DOX are clearly detectable within the brain lesions 75 min postadministration. Collectively, results from this study demonstrate that through intercalation of a cytotoxic drug into the bifunctional aptamer, a therapeutic delivery vehicle can be developed for specific targeting of EpCAM-positive brain metastases.
URI: http://ahro.austin.org.au/austinjspui/handle/1/22561
DOI: 10.1089/nat.2019.0807
ORCID: 0000-0001-8932-5116
PubMed URL: 32027209
Type: Journal Article
Subjects: aptamer
blood brain barrier
cancer
therapeutic
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.